Radiopharm RAD101 Phase 2B Hits 90% Primary Endpoint

TL;DR

**Radiopharm's RAD101 drug just crushed its Phase 2B trial with 90% success!**

AI Summary

Radiopharm Theranostics Ltd filed a 6-K on March 24, 2026, announcing positive interim Phase 2B data for its drug RAD101. The filing states that 90% of patients achieved the primary endpoint, which is a significant milestone for the company. This matters to investors because successful clinical trial results can dramatically increase a drug's potential market value and the company's stock price, as it moves closer to commercialization.

Why It Matters

Positive clinical trial results for RAD101 could lead to faster drug approval and higher future revenues for Radiopharm Theranostics, directly impacting its stock valuation.

Risk Assessment

Risk Level: medium — While positive, this is interim Phase 2B data, and future trials or regulatory hurdles could still impact the drug's path to market.

Analyst Insight

A smart investor would closely monitor Radiopharm Theranostics Ltd for further announcements regarding RAD101's development and potential regulatory submissions, as this positive interim data could signal significant future value.

Key Numbers

• 90% — Primary Endpoint Achievement (Indicates strong efficacy for RAD101 in its interim Phase 2B trial.)

Key Players & Entities

• Radiopharm Theranostics Ltd (company) — the filer of the 6-K and developer of RAD101
• RAD101 (drug) — the drug with positive interim Phase 2B data
• 90% (number) — percentage of patients achieving the primary endpoint in the Phase 2B trial
• March 24, 2026 (date) — filing date of the 6-K and period of report

Forward-Looking Statements

• Radiopharm Theranostics Ltd's stock price will increase due to positive clinical trial results. (Radiopharm Theranostics Ltd) — high confidence, target: 2026-03-25
• RAD101 will advance to further clinical trials or regulatory review. (RAD101) — high confidence, target: 2027-03-24

FAQ

Filing Documents

• ea0283164-6k_radiopharm.htm (6-K) — 13KB
• ea028316401ex99-1.htm (EX-99.1) — 30KB
• ea028316401_ex99-1img1.jpg (GRAPHIC) — 4KB
• 0001213900-26-033188.txt ( ) — 49KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on March 24, 2026 titled: “RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: March 24, 2026 By: /s/ Phillip Hains Phillip Hains Company Secretary 3

View Full Filing

View this 6-K filing on SEC EDGAR